Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Recurrent Ovarian Cancer
NCT06365853Phase 2Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Jul 2024
- Primary completion
- Feb 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 7
01
Overview
A Phase 2 trial of mirvetuximab soravtansine in ovarian cancer, sponsored by AbbVie Inc.. Started Jul 2024; status: active, not recruiting.
02
Drugs
mirvetuximab soravtansine
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT06365853.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06365853.